Intellia Therapeutics Presents New Data on Expanded Cell Engineering Capabilities Utilizing Base Editors
March 25 2021 - 6:30AM
Intellia Therapeutics, Inc. (NASDAQ:NTLA) will present the first
preclinical data set on its novel cytosine deaminase base editor
technology at the seventh Cold Spring Harbor Laboratory (CSHL)
virtual scientific meeting on Nucleic Acid Therapies. The data
shows how the Company’s proprietary base editors can expand its
genome editing capabilities by enabling the introduction of
multiple gene knockouts simultaneously with no detectable increase
in translocation above background levels. The meeting is being held
virtually from March 24-26, 2021.
“At Intellia, we continue to build the broadest and deepest
genome editing platform for developing potentially curative
treatments for severe diseases,” said Intellia President and Chief
Executive Officer John Leonard, M.D. “We are quite pleased to share
the expansion of our ex vivo toolbox to include base editing, which
perfectly complements our existing cell engineering and editing
capabilities. We believe our scientific innovation in advancing
this novel technology will support our development of a broad
portfolio of cancer and autoimmune therapies.”
Presentation Details
Title: “Special Edition: Expanding
Intellia’s Toolbox with Base Editing”
Session: Gene EditingDate and
Time: March 25, 2021, 9:30 a.m. – 12:30 p.m.
ETPresenting Author: Christian Dombrowski,
senior director of Intellia’s Gene Editing Platform group
Data Summary:
- Intellia has developed a therapeutically relevant cytosine
deaminase base editor that is equipotent to Cas9 for T cell
editing
- The combination of Intellia’s base editor with its proprietary
cell engineering process achieved >90% T cell editing efficiency
while maintaining translocations at background levels
The presentation can be found here, on the Scientific
Publications & Presentations page of Intellia’s
website.
Title: “New Era of Genome Editing: In Vivo,
Liver-Directed CRISPR Candidates for Rare
Diseases”Session: Nucleic Acid Clinical
Programs Date and Time: March 26, 2021, 2:30 –
5:30 p.m. ETPresenting Author: Laura
Sepp-Lorenzino, Ph.D., chief scientific officer, Intellia
Therapeutics
About Intellia TherapeuticsIntellia
Therapeutics is a leading clinical-stage genome editing company,
focused on the development of proprietary, potentially curative
therapeutics using the CRISPR/Cas9 system. Intellia believes the
CRISPR/Cas9 technology has the potential to transform medicine by
both producing therapeutics that permanently edit and correct
disease-associated genes in the human body with a single treatment
course, and creating enhanced engineered cells that can treat
oncological and immunological diseases. Intellia’s combination of
deep scientific, technical and clinical development experience,
along with its leading intellectual property portfolio, puts it in
a unique position to unlock broad therapeutic applications of the
CRISPR/Cas9 technology and create new classes of therapeutic
products. Learn more about Intellia and CRISPR/Cas9 at
intelliatx.com. Follow us on Twitter @intelliatweets.
Forward-Looking StatementsThis press release
contains “forward-looking statements” of Intellia Therapeutics,
Inc. (“Intellia”, “we” or “our”) within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, express or implied
statements regarding Intellia’s beliefs and expectations regarding
our: development of our gene editing tools and modular platform to
advance our genome editing capabilities; application of any of our
gene editing tools in successful preclinical, clinical, or
commercial products, advancement and expansion of our CRISPR/Cas9
technology to develop human therapeutic products; ability to
demonstrate our platform’s modularity and replicate or apply
results achieved in preclinical studies, in any future studies,
including human clinical trials; ability to develop in vivo or ex
vivo cell therapeutics of all types using CRISPR/Cas9 technology;
and ability to expand, maintain and protect our intellectual
property rights, including patents and licenses.
Any forward-looking statements in this press release are based
on management’s current expectations and beliefs of future events,
and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those
set forth in or implied by such forward-looking statements. These
risks and uncertainties include, but are not limited to: risks
related to our ability to protect and maintain our intellectual
property position; risks related to our relationship with third
parties, including our licensors and licensees; risks related to
the ability of our licensors to protect and maintain their
intellectual property position; uncertainties related to regulatory
agencies’ evaluation of regulatory filings and other information
related to our product candidates; uncertainties related to the
authorization, initiation and conduct of studies and other
development requirements for our product candidates; the risk that
any one or more of our product candidates, including those that are
co-developed, will not be successfully developed and
commercialized; and the risk that the results of preclinical
studies or clinical studies will not be predictive of future
results in connection with future studies. For a discussion of
these and other risks and uncertainties, and other important
factors, any of which could cause Intellia’s actual results to
differ from those contained in the forward-looking statements, see
the section entitled “Risk Factors” in Intellia’s most recent
annual report on Form 10-K as well as discussions of potential
risks, uncertainties, and other important factors in Intellia’s
other filings with the Securities and Exchange Commission (“SEC”).
All information in this press release is as of the date of the
release, and Intellia undertakes no duty to update this information
unless required by law.
Intellia Contacts:
Investors:
Lina LiDirector Investor
Relations+1-857-706-1612lina.li@intelliatx.com
Media:
Julie Ferguson Interim Head of External Affairs &
Communications+1-312-385-0098Julie.ferguson@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jul 2023 to Jul 2024